Skip to content

Study · Randomized controlled trial · n = 79 · 2020

9 results

Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.

Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS

Diabetes, obesity & metabolism29 Jul 2020Cited by 39 (Europe PMC)

PMID32573927 (opens in a new tab)PMCIDPMC8009602 (opens in a new tab)DOI10.1111/dom.14121 (opens in a new tab)PepBankPUB-32573927
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In participants with T1D, exenatide ER did not significantly lower HbA1c versus placebo at week 24.

    In plain wordsIn people with T1D, exenatide did not significantly lower HbA1c versus placebo at week 24.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c at week 24
    Study

    n = 79

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Measurements

    LS mean HbA1c at week 24
    7.76%
    exenatide ER group
    LS mean HbA1c at week 24
    8%
    placebo group

    Source sentences

    Summary
    At week 24, the time of the primary outcome, the least squares (LS) mean HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER group versus 8.0% (95% CI 7.64, 8.35) in the placebo group (P = 0.08).
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with T1D, exenatide ER lowered HbA1c versus placebo at week 12.

    In plain wordsIn people with T1D, exenatide lowered HbA1c versus placebo at week 12.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c at week 12
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Measurements

    LS mean HbA1c at week 12
    7.71%
    exenatide ER group
    LS mean HbA1c at week 12
    8.05%
    placebo group

    Source sentences

    Summary
    At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group (P = 0.01).
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In T1D, exenatide ER reduced weight versus placebo at week 12.

    In plain wordsIn T1D, exenatide reduced weight versus placebo at week 12.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight at week 12
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    Those treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated with placebo (P <0.001 and P = 0.007).
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In T1D, exenatide ER reduced weight versus placebo at week 24.

    In plain wordsIn T1D, exenatide reduced weight versus placebo at week 24.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight at week 24
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    Those treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated with placebo (P <0.001 and P = 0.007).
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In T1D, total insulin dose was lower with exenatide ER than placebo, regardless of residual insulin production.

    In plain wordsIn T1D, total insulin dose was lower with exenatide than placebo, regardless of residual insulin production.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal insulin dose
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production.
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In T1D, weight-corrected insulin dose was not lower with exenatide ER than placebo.

    In plain wordsIn T1D, weight-corrected insulin dose was not lower with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeWeight-corrected insulin dose
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production.
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  7. 07HumanRandomized controlled trialSafety outcome

    In T1D, adverse events were more frequent with exenatide ER than placebo.

    In plain wordsIn T1D, adverse events were more frequent with exenatide than placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAdverse events
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased.
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  8. 08HumanRandomized controlled trialSafety outcome

    In T1D, exenatide ER did not increase hypoglycaemia versus placebo.

    In plain wordsIn T1D, exenatide did not increase low blood sugar versus placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHypoglycaemia
    Study

    n = 79

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased.
    2 context sentences
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In T1D, participants with detectable C-peptide mainly drove the HbA1c improvement with exenatide at week 12.

    In plain wordsIn T1D, participants with detectable C-peptide mainly drove the HbA1c improvement with exenatide versus placebo at week 12.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c response by C-peptide status
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mcg weeklyAs given in this study (human).

    Source sentences

    Summary
    The improvement at week 12 was driven mainly by those with detectable levels of C-peptide.
    3 context sentences
    Summary · context
    At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group (P = 0.01).
    Summary · context
    We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide.
    Summary · context
    Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.